and were also excluded from the study. In total, 13 patients in protocol-1 (mean age, 56.8±12 years, 8 males/5 females) and 10 in protocol-2 (58.1±7.2 years, 6 males/4 females) were included, and of these 23 patients, 5 had blood glucose concentrations greater than 7 mmol/L and were provisionally diagnosed as having diabetes according to the criteria of the Japanese Diabetic Association. In protocol-2, patients were initially instructed to walk more than 10,000 steps a day and 8 weeks later, temocapril was added to the regeimen. After each treatment BP and blood chemistry data were obtained. Written informed consent was obtained from all patients. The protocols were approved by the Ethical Committees of Tokushima University Hospital and Kagawa Prefectural Hospital.
Blood glucose was measured by an automated enzymatic method and blood insulin by an immunoradiometric assay (Insulin Riabead II kit, Dianabot, Tokyo, Japan).
Statistical Analysis
Data are expressed as the mean ± SD. Data were analyzed by analysis of variance plus Bonferroni multiple comparison tests. A p value of less than 0.05 was accepted as statistically significant.
Results
Baseline characteristics were not significantly different between the 2 patients groups: body mass index (BMI) (protocol-1 23.9±3.0 kg/m 2 vs protocol-2 23.6±2.8 kg/m 2 ); systolic BP (156.2±12.3 mmHg vs 165.0±14.0 mmHg); diastolic BP (85.6±10.7 mmHg vs 86.4±10.0 mmHg); fasting plasma glucose (6.6±1.0 mmol/L vs 6.3±1.5 mmol/L); and fasting plasma insulin (107±16 vs 116±49 pmol/L). As in Table 1 , body weight was not altered significantly by either treatment. Patients walked 5,721±1,425 and 5,119±1,957 steps at baseline in protocols-1 and -2, respectively. After instruction they walked 10,980±2,558 and 11,285±2,456 steps a day at least 3 days weekly in protocols-1 and -2, respectively. Table 1) Systolic and diastolic BP were significantly lowered by temocapril alone, but not significantly by walking alone. The combination of both temocapril and walking lowered BP further in both protocols.
Change in BP (

Plasma Concentrations of Glucose, Insulin and Lipids (Table 2)
Walking exercise and temocapril treatment each decreased the plasma insulin concentrations significantly, and the combination of temocapril and walking significantly decreased the fasting concentration of plasma glucose. Temocapril-treatment or walking alone significantly decreased the HOMA-R, and the combination of both treatments further lowered HOMA-R (Fig 1) . Hemoglobin (Hb) A1c was slightly but significantly improved by the combination therapy in both protocols. Blood concentration of triglyceride was lower in walking and the combination of both treatments than in baseline. There were no significant differences in serum concentrations of total cholesterol or high density lipoprotein (HDL)-cholesterol in each treatment group.
Discussion
In the present study, temocapril, an ACEI, and an increase in walking distance improved HOMA-R in insulin-resistant hypertensive patients; however, the lipid profile was not improved. The most important finding is that the combination of exercise and ACEI greatly improved the impaired glucose metabolism.
Insulin sensitivity is usually measured by assessing the relation between plasma insulin and an insulin-dependent metabolic variable, such as plasma glucose. The euglycemic hyperinsulinemic clamp is the gold standard for measuring insulin sensitivity, 12, 13 but the need to repeat the plasma glucose sampling makes it both intensive labor and costly. HOMA-R 14 is a useful method not only for diagnosing insulin resistance, but also for follow-up during the treatment of patients with type 2 diabetes; 15, 16 it has been reported that HOMA-R closely correlated with the euglycemic hyperinsulinemic clamp. 17 Kishimoto et al also found that low-intensity exercise, such as walking, improved the HOMA-R; 18 however, it is still controversial whether or not low-intensity exercise improves insulin resistance. The reason for the discrepancy is not known. One possible explanation is the insulin secretion ability of the cells. As exercise itself cannot substitute for insulin in patients with inadequate secretion, only a minimal improvement of glucose tolerance has been observed in type 2 diabetic patients with marked insulin deficiency. 19, 20 The patients in the present study had high insulin concentrations but only slightly increased blood glucose concentrations, suggesting that their insulin secretion was not severely impaired and it is in such patients that exercise can most effectively improve insulin action and lower the fasting blood concentrations of insulin.
In the present study, the decrease in fasting blood glucose was minimal or none with walking or temocapril alone, although blood insulin was significantly decreased by either treatment alone or in combination of for 8-16 weeks, which would be the main explanation for the decrease in HOMA-R. In contrast to our study, Katsuki et al found that both fasting concentrations of insulin and glucose were lowered by a combination of diet and walking therapy, 15 and the discrepancy in results might be related to the background of the patients as well as the combination therapy. In their study, there were more patients with a higher fasting blood glucose concentrations and a lower blood insulin than in the present study. We instructed the patients to walk more, but not to reduce food intake, and the stability in body weight despite walking longer distances suggests that the patients ate more after starting exercise. Therefore, our data suggest that insulin resistance, as indicated by HOMA-R, was improved more easily than the serum concentrations of total cholesterol and HDL-cholesterol. The serum concentration of triglycerides showed a slight but significant improvement in protocol-2, but not in protocol-1, which suggests that either drug or exercise more effectively improve insulin resistance than the serum lipid profile in insulin-resistant hypertensive patients.
The improving effect of ACEI was once attributed to an increased blood flow, leading to increased delivery of glucose and insulin to the peripheral tissues. 21, 22 In our previous studies we found the combination of temocapril and exercise training improved insulin resistance in a rat model of type 2 diabetes, but not by losartan, an angiotensin-receptor antagonist. 23 In vitro and in vivo studies have found that the improving effect of ACEI on glucose utilization is blocked by a kinin antagonist, 27, 28 which suggests a contribution by kinins in increased insulin sensitivity. However, some studies reported that the contribution of BK was minimal or none in ACEI-induced insulin sensitivity 23, 24 and the reason for the discrepancy is not known. However, these results indicate that improvement in insulin resistance is mediated by many pathways.
Exercise increases the uptake of the glucose, 29 but the signaling pathways related to increased glucose uptake differ between insulin-and exercise-mediated stimulation. 30 The molecular basis for this phenomenon has not been completely elucidated but appears to be dependent on multiple factors, including muscle glycogen concentrations, humoral factors and autocrine/paracrine mechanisms. Exercise training augments the plasma concentration of kallikrein or skeletal muscle phospholipase A2 activity, which is a target of BK and leads to prostaglandin synthesis, and there is a positive correlation between these increased parameters and muscular glucose uptake. 31 Increased kallikrein also occurs in skeletal muscle with high oxidative activity, 32 a finding that may be related to the observation of Stebbins et al that the contraction of the skeletal muscle enhanced the release of BK. 10 Given these findings, it is possible that during exercise BK may be highly involved in increased glucose uptake from the circulation. We also consider that there are other mechanisms because improvement in insulin resistance by ACEI or exercise is mediated by a number of factors. However, the potentiated improvement of glucose metabolism induced by a combination of exercise training (increased BK release) and ACEI (decreased degradation of BK) is an effective, and reasonable treatment for hypertensive patients with insulin resistance.
